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Sporadic implementation of UK familial mammographic
surveillance guidelines 15 years after original publication
D. Gareth Evans1,2,3, Maria Edwards3, Stephen W. Duffy4, Cancer Genetics Group clinical leads and Marc Tischkowitz5
The National Institute of health and Care Excellence issued guidelines on familial breast cancer screening in 2004. Such guidelines
should be uniformly implemented to ensure that members of the same family with the same level of risk, but living in different
areas, have the same access to screening. We assessed uptake by creating a short, six question online survey designed to assess
compliance in each regional area. We used this to conduct a survey of all 22 regional genetics services. There was a 100% response
to the survey allowing a complete map to be created. The devolved nations had near complete compliance with the sole exception
of SW Scotland, but in England the picture was fragmented with regions representing a combined population of 26.6 million (48%)
not implementing the full NICE recommendations. Fifteen years after the publication of the original guidelines, major inequity in
provision for screening still occurs and a postcode lottery exists for the management of women from families with a history of
breast cancer. We estimate that up to 73 preventable breast cancer deaths occur each year due to the current inequity of access. It
may be time to consider alternative funding and implementation models to ensure consistent access across the country.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0631-2
BACKGROUND
Guidelines are an important mechanism to ensure equitable and
evidence-based delivery of medical care. In the UK (England &
Wales) the National Institute of health and Care Excellence (NICE)
was created 20 years ago with a strapline of ‘Improving health and
social care through evidence-based guidance’. When the term
‘offer’ is utilised this infers that health commissioners should
implement the recommendation as it has usually passed the test
of being cost effective. Although guidelines are just ‘guidance’, the
purpose of NICE guidelines was to avoid postcode lotteries where
an individual in one part of a country was able to access an aspect
of healthcare, whereas in another part they would be refused
access. While some have intimated that that individual guidance
could be ignored if it was not in the patient’s interest to follow it,1
even if it was NICE guidance, this is not the same as health
commissioners deciding whether or not to provide the financial
requirements to deliver guidance for large groups of people.
Breast screening is an important element of what can be
offered to women at increased risk of breast cancer by virtue of
their family history. Targeting such screening at those at higher
risk reduces the negative elements of screening such as concerns
regarding what is often termed ‘overdiagnosis’. Women who have
seen a mother or sister die from breast cancer before 50 years of
age will be concerned about having to wait until age 50, the usual
starting age for national programmes to undergo mammography
screening.2 Many countries have produced guidelines including
frequently updated guidance in the USA,3 Netherlands4 and
France.5 The first NICE guideline group for familial breast cancer
was constituted in 2002 and produced its first report in May 2004.6
This recommended that women at moderate (lifetime risk
17–29%; 10-year risk aged 40 of ≥3%) and high risk (lifetime risk
≥30%; 10-year risk aged 40 of ≥8%) should be ‘offered’ annual
mammography screening aged 40–49 years of age. It was
acknowledged that a national study (FH01) was in progress and
would inform a future update.7,8 A short update in 2006,6
recommended MRI screening for women at very high risk
including carriers of pathogenic variants in BRCA1, BRCA2 and
TP53 aged 30–49 years based at least in part on the UK MARIBS
study results.9 The 2013 update6 was able to include the results of
the FH01 mammography screening trial in women aged 40–49
and strengthen the recommendation to offer annual mammo-
graphy aged 40–49 for moderate-risk and 40–59 for high-risk
women. The FH01 study8 showed a projected mortality advantage
for annual mammography surveillance compared to age matched
women with no screening based on tumour characteristics at
diagnosis. Approximately 3% of women aged 40 years are at
moderate or high-risk of breast cancer based on family history
alone,9 and at least half of these come forward with concerns.10
Some women at moderate risk were still able to access
mammographic screening aged 40–49 years at least through
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the FH01 trial8 that included 76 centres across the UK, but
anecdotal evidence between 2006–2011 pointed to patchy
implementation of MRI screening. As a result, the National
Health Service Breast Screening Programme (NHSBSP) was
asked to deliver the MRI aspects of NICE guidance. In January
2012 the Advisory Committee on Breast Cancer Screening
agreed to implement this and there is now equitable provision
of MRI screening (aged 30–49) and annual mammography
screening from 40-69 years in BRCA1, BRCA2 and TP53 carriers
(no mammography for TP53) in England.11 The protocol for MRI
screening included those at ‘equivalent’ high risk to a BRCA1/
BRCA2 mutation carrier. This was misinterpreted by a number
of clinics to include all those at high-risk of breast cancer. In
reality only about 8–10% of high-risk women qualify for the
NHSBSP higher risk programme10,12 and the protocols have
now been rewritten to clarify this. However, this uncertainty
has led to many family history clinics (FHCs) not being
commissioned to deliver the NICE defined high-risk annual
screening to age 59 years.
These concerns over the reduction in availability of NICE
recommended mammography screening led us to survey all UK
genetics centres delivering cancer genetics services.
METHODS
A short, six question online survey was designed (supplementary
table) to assess compliance in each regional area. The invitation
was sent out on 14 March 2019 to all cancer genetics leads from
the Cancer Genetics Group (http://www.ukcgg.org/) covering 22
regional centres.
Fully available including
<40
All screening aged 40–59
fully available none <40
Only moderate fully
Only high fully
Neither fully
Created with mapchart.net ©
Fig. 1 Map of mammographic screening provision by regional genetics centre. CCGs within each region are not shown, nor is the variation in
provision by CCGs within a region. It is therefore possible that a CCG within a “non-compliant” region may be fully compliant and vice versa.
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RESULTS
There was a 100% response to the survey allowing a complete
map to be created. The devolved nations of Wales, Northern
Ireland and Scotland had near complete compliance with the NICE
recommended mammography screening ‘offer’ with the sole
exception of parts of SW Scotland that only screened moderate-
risk women 2-yearly (Fig. 1; Table 1). In England the picture was far
patchier with regions representing a combined total population of
26.6 million (48% of the total population) not supplying all NICE
recommended mammography screening. Regions covering 10.4
million people did not have coverage for Moderate-risk screening
and in some areas moderate-risk screening was only available to
those carrying pathogenic variants in “moderate risk” genes such
as ATM or CHEK2, which represent only a tiny proportion of all
those potentially eligible.
DISCUSSION
NICE guidelines are considered as providing high-level evidence
and are often utilised around the world.13 We have shown that 15
years after the original NICE guidance to offer annual mammo-
graphy screening to women at moderate-risk aged 40–49 there is
still patchy provision across England in particular. Based on the
results we can attempt to estimate the possible impact of the
observed discrepancies in screening. From Table 1, 10.4 million
individuals (7.4 million+ 3 million) live in areas not receiving the
recommended surveillance for moderate risk. Thus, we estimate
that up to 16.4% of eligible women (10.4/63.35 million) are not
receiving the appropriate moderate-risk surveillance. Of the 4.3
million women aged 40–49 in the UK, it is estimated that 8% have
ten-year risk in excess of 3% at age 40, that is 344,000 women.9
From the above, up to 16.4% of these are not receiving the
recommended annual mammography surveillance, i.e. 56,416
women. In the FH01 study, it was estimated that 7.8 breast cancer
deaths are prevented in this population per 10,000 surveillance
episodes.14 Thus, up to 44 breast cancer deaths year would be
prevented if the guidelines were fully adhered to.
The provision for high-risk screening in women aged 40–59 is
even worse meaning that women at higher levels of breast cancer
risk in their 40’s are unable to access screening. This is despite
strengthening in the evidence base in the 2006 and 2013 updates
to the familial breast cancer guidance.6 From Table 1, it is
estimated that up to 42% of the population (26.6/63.35) live in
areas not covered by the currently recommended high-risk
surveillance. Of the 8.85 million women aged 40–59, it is
estimated that 1%, 88,500, are eligible, and that up to 42% of
these (37,167 women) are not receiving the appropriate
surveillance. Although we do not have formal estimates of the
absolute benefit of this surveillance, it is reasonable to assume
that it is at least as effective as the moderate-risk surveillance.
Thus, we estimate that up to 29 deaths per year would be
prevented in the high-risk population if the guidelines for
surveillance were followed.
With the recent publication of evidence that annual mammo-
graphy screening in women aged 35–39 years at enhanced breast
cancer risk appears equally effective at early detection12
compared to age 40–49,8 NICE is likely to evaluate this at the
next update.6 However, one would have little confidence that any
recommendation to offer screening aged 35–39 years would be
fully implemented, despite the fact that women from regions
covering a population of around 14.5 million appear to already get
this (Table 1).
In the USA in 2007, the American Cancer Society (ACS) published
recommendations for annual breast MRI along with annual
mammography screening for women who have ≥20% lifetime
risk for developing breast cancer incorporating both the majority
of the UK moderate risk and all of the high-risk group.15 A survey in
2012 showed low access to MRI, although, understandably this wasT
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higher amongst those with health insurance.16 Overall there is
relatively little published on adherence to breast screening
guidelines internationally. That may be because it is difficult to
audit or that it has not been explored. The Clinical Commissioning
Groups (CGGs) look to save money and therefore are not willing to
adopt all NICE guidelines. Not implementing this guidance would
save on not having to provide funding for family history clinics for
women to be assessed for BC risk. While CGGs appear to be able to
ignore guidance, there are precedents to suggest that they could
be successfully sued for not implementing NICE guidance without
good reason (https://www.nice.org.uk/news/article/court-warns-
ccg-over-disagreeing-with-nice-guidance). If CGGs were forced to
adopt NICE guidelines this would reduce inequalities of access.
Alternatively, all familial breast screening could be incorporated
into the NHSBSP, which would also lead to more uniform access.
Finally, it is important to educate and inform all women to have a
breast cancer risk assessment by age 40 years, either through their
GP or by developing tailored online tools to enable a self-
assessment.
CONCLUSION
We have shown that there has been only partial compliance with
NICE approved mammographic screening surveillance in women
at familial risk with less than half of England is now fully compliant.
This has created a postcode lottery where women in one part of
the UK get access to surveillance that their sister at the same risk
cannot. It is a concern that even in a fully funded public health
system such as the UK that major inequity in provision occurs even
with the highest levels of evidence provided by NICE guidelines.
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